MedPath

Role of L-Ornithine L-Aspartate in improving acute encephalopathy (altered sensorium) in patients with Liver Cirrhosis

Phase 4
Conditions
Health Condition 1: null- Hepatic cirrhosis
Registration Number
CTRI/2013/02/003360
Lead Sponsor
Department of Gastroenterology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
164
Inclusion Criteria

a. Hepatic cirrhosis based on clinical, biochemical, radiological and/or histological data.

b. Patients with overt acute grade 2, 3 and 4 HE, according to the West Haven criteria.

c. Age of patient >18 years

d. Patients with or without a precipitating factor for the HE.

Exclusion Criteria

a.Patients who are terminally ill (End Stage Liver Disease, MELD more than 15)

b.Chronic HE, on Lactulose or antibiotics

c.Acute superposed liver injury (hepatitis) or acute on chronic liver failure

d.Severe septicemia with shock

e.Hepatocellular carcinoma

f. Wilsonâ??s disease as the etiological factor of liver disease

g. Advanced cardiac or pulmonary disease

h.Acute renal failure or end stage renal disease

i.Neuro-degenerative disease or major psychiatric illness

j.Patients on sedatives or antidepressants

k.Pregnancy or breastfeeding

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mental state gradeTimepoint: 5 days
Secondary Outcome Measures
NameTimeMethod
Blood ammonia levels <br/ ><br> <br/ ><br>Timepoint: 5 days;Hospital stayTimepoint: 4 weeks;MortalityTimepoint: 4 weeks
© Copyright 2025. All Rights Reserved by MedPath